( NASDAQ-NMS:JAZZ )

News from Jazz Pharmaceuticals plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

16:05 ET Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 first quarter financial results on Tuesday, May 8, 2018, after...


Mar 06, 2018, 16:05 ET Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming...


Mar 02, 2018, 08:30 ET Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with standard...


Feb 27, 2018, 16:05 ET Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2017 and provided financial...


Feb 23, 2018, 08:30 ET Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the...


Feb 13, 2018, 16:05 ET Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 fourth quarter and full year financial results on Tuesday,...


Feb 08, 2018, 16:15 ET National Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos™ (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN®) added Vyxeos™ (daunorubicin and...


Jan 02, 2018, 16:05 ET Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 36th Annual J.P....


Dec 21, 2017, 08:30 ET Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on...


Dec 07, 2017, 16:05 ET Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the BMO Capital Markets...


Dec 04, 2017, 16:05 ET Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Daniel N. Swisher, Jr. as president and chief operating officer,...


Nov 09, 2017, 16:05 ET Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at three upcoming investor...


Nov 07, 2017, 16:05 ET Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2017 and updated financial guidance for...


Nov 03, 2017, 08:30 ET Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines...


Nov 01, 2017, 09:16 ET Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that thirteen abstracts spanning the company's hematology/oncology portfolio will be...


Oct 24, 2017, 16:05 ET Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 third quarter financial results on Tuesday, November 7, 2017,...


Sep 12, 2017, 08:30 ET Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company was named to Fortune magazine's list of fastest growing companies for...


Sep 01, 2017, 12:36 ET Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that the initial purchasers of the recently announced private...


Aug 30, 2017, 16:05 ET Jazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Wells Fargo...


Aug 29, 2017, 06:30 ET Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the companies have entered into a collaboration and...


Aug 18, 2017, 07:00 ET Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced an offering by Jazz Investments I Limited, its wholly-owned...


Aug 17, 2017, 16:07 ET Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an offering by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), of...


Aug 08, 2017, 16:05 ET Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results

Received FDA Approval of Vyxeos for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with...


Aug 03, 2017, 10:15 ET Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, August 7, 2017 at 4:30 p.m. EDT/9:30 p.m....